Citizens JMP raised the firm’s price target on HealthEquity (HQY) to $117 from $110 and keeps an Outperform rating on the shares. HealthEquity reported Q1 results and increased the lower end of its fiscal 2026 revenue outlook and adjusted EPS view, the analyst tells investors in a research note. The firm believes that enhanced security measures will prove successful at neutralizing fraud.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- Strong Financial Performance and Strategic Growth Opportunities Drive Buy Rating for Healthequity
- Healthequity’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
- HealthEquity, Inc. Reports Strong Q1 2026 Results
- Closing Bell Movers: Guidewire up 11% after Q3 beat, guidance raise
- HealthEquity sees FY26 EPS $3.61-$3.78, consensus $3.62